Cure My Disease

Don't miss your cure!

 Log in / Sign up

CPAP may tame blood pressure in sleepy sleep apnea patients

NCT ID NCT05742360

Disease control Sponsor: Ohio State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study investigates whether using CPAP therapy for six months can reduce average 24-hour blood pressure in people with moderate-to-severe obstructive sleep apnea who also report excessive daytime sleepiness. Participants are adults aged 18-75 with elevated blood pressure and a confirmed sleep apnea diagnosis. The main goal is to measure changes in blood pressure using a portable monitor worn for a full day.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CPAP therapy (a device that delivers continuous positive airway pressure during sleep)
What this could lead to
If successful, this could show that treating sleep apnea with CPAP significantly lowers blood pressure in a specific subgroup of patients who are very sleepy.
What could go wrong
This is a medium-sized trial focused on a specific subtype, so results may not apply to all sleep apnea patients. Blood pressure improvements may be modest or not clinically significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 227 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults between the ages of 18 to 75 years old with moderate-severe obstructive sleep apnea (OSA) with excessively sleepy symptom subtype. OSA diagnosis will be defined as an apnea/hypopnea index (AHI) \>or =5 episodes per hour.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-75 years * Moderate-severe OSA (defined as ODI ≥10 events/hour) via Polysomnography (PSG) or Home Sleep Apnea Study (HSAT) done based on clinical grounds * Excessively sleepy subtype determined by patient-reported symptoms * Willing to accept CPAP therapy * An elevated baseline office BP defined as ≥120 or ≥80 mmHg * Planned PAP (CPAP or bi-level PAP) treatment by treating provider Exclusion Criteria: * Recent changes (within 3 months) to BP medications among those who are on these medications * Unable to apply ABPM cuff * Current use of CPAP or other OSA treatments * Resting, awake SaO2 \<90% or use of home oxygen therapy * New York Heart Association (NYHA) categories III-IV of heart failure * Presence of Cheyne-Stokes Respiration (CSR) in sleep study identified by typical crescendo-decrescendo pattern of respiration with associated apneas and/or hypopneas in the absence of inspiratory flow limitation * Predominantly central sleep apnea (AHI≥15 events/hour, with \>50% central events \[apnea or hypopnea\]) * Life expectancy \<2 years * Pregnancy * Clinical history of chronic kidney disease (Stage 5) requiring dialysis, or renal transplant * Systolic BP \> 180 mmHg

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obstructive sleep apnea are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obstructive sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obstructive sleep apnea

Contacts and locations

Locations

  • The Ohio State University - Martha Morehouse Medical Pavilion, Suite 2600

    Columbus, Ohio, 43221, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.